Note 2 - Acquisitions (Tables)

12 Months Ended

Jun. 30, 2016

	Zephyrus		Cliniqa		Novus		Protein Simple		CyVek			Bionostics		PrimeGene

Current assets	$	86	$	11,926	$	10,739	$	19,660	$	1,206		$	9,605	$	1,272
Equipment		32		1,436		1,266		1,983		971			2,180		546
Other long-term assets				58		40		554		19
Intangible Assets:
In process research and development		7,400		-		-		-		-			-		-
Developed technology		-		18,000		5,010		39,200		20,200			14,400		2,200
Trade name		-		1,100		5,300		36,100		100			2,700		3,000
Customer relationships		-		27,000		14,400		101,600		600			41,000		9,100
Non-compete agreements		-		-		-		200		-			2,400		322
Goodwill		6,878		42,669		28,408		134,074		91,658			56,349		5.518
Total assets acquired		14,396		102,189		65,163		333,371		114,754			128,634		21,958

Liabilities		54		1,508		2,166		11,644		1,965			3,007		887
Deferred income taxes, net		2,812		17,793		2,875		21,674		(438	)		22,478		2,310
Net assets		11,530		82,888	$	60,122	$	300,053	$	113,227		$	103,149	$	18,761
Less fair-value of previous investment		-		-		-		-		18,300			-		-
Net assets acquired		11,530		82,888		60,122		300,053		94,927			103,149		18,761

Cash paid, net of cash acquired	$	8,030	$	82,888	$	60,122	$	300,053	$	59,927		$	103,149	$	6,031
Note Payable		0		0		0		0		0			0		12,730
Contingent consideration payable		3,500		-		-		-		35,000			-		-
Net purchase price	$	11,530	$	82,888	$	60,122	$	300,053	$	94,927		$	103,149	$	18,761